OFFICIAL PUBLICATION OF

by its subsidiary APPco

Vyvanse shortage ‘resolved’

AJP Staff 01/05/2024

TGA declares supply issues impacting ADHD medication Vyvanse to be “resolved” Takeda Pharmaceuticals Australia is reporting that supply shortages are no longer impacting its Vyvanse (lisdexamfetamine dimesilate) capsules. Shortages had impacted various strengths of the medication, with the Therapeutic Goods Administration (TGA) reporting that supplies of Vyvanse 50mg capsules had been resolved as of 7 March,

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

In scarce supply

I love a good joke.

Evan Nickols

Concurrent funding for aged care pharmacists and RMMRs needed

I understood that was to happen as a gradual changeover and not an abrupt cessation. Currently we do not have…

Jenny Gowan

‘We need more pharmacists’

Could start with ensuring the owner at least lives in the STATE of the pharmacy he owns , first

geoffrey colledge

‘We need more pharmacists’

My view of the problem is a fault lying with the universities. There are mainly overseas students and predominantly female…

geoffrey colledge

Vyvanse shortage ‘resolved’

Previous Actions speak louder than words

Next Harmonise RSV vax rules: PSA

Ceramides: what are they and why are they important?

In the beginning

The signs of ageing

Hyperpigmentation

MENU

Previous Actions speak louder than words

Next Harmonise RSV vax rules: PSA

Related Posts

MENU

Hi there! 👋 Looks like you’re not logged in.